Data gathered: April 23
AI Stock Analysis - Intra-Cellular Therapies (ITCI)
Analysis generated June 29, 2024. Powered by Chat GPT.
Intra-Cellular Therapies (ITCI) is a biopharmaceutical company focused on the development of novel therapies for the treatment of central nervous system (CNS) disorders. The company’s flagship product, CAPLYTA (lumateperone), is approved in the US for the treatment of bipolar depression and schizophrenia in adults. Intra-Cellular Therapies is committed to addressing significant unmet needs in the psychiatric and neurodegenerative market, investing heavily in R&D to broaden its therapeutic portfolio.
Stock Alerts - Intra-Cellular Therapies (ITCI)
 |
Intra-Cellular Therapies | April 21 Job postings are down by 28.5% in the last couple of days. |
|
Intra-Cellular Therapies | April 19 Job postings are down by 28.5% in the last couple of days. |
|
Intra-Cellular Therapies | April 11 Josh Gottheimer (member of U.S. congress) is selling shares |
|
Intra-Cellular Therapies | April 10 Job postings are down by 18.7% in the last couple of days. |
Alternative Data for Intra-Cellular Therapies
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 60 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 2 | Sign up | Sign up | Sign up |
| Patents | 146 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,051 | Sign up | Sign up | Sign up |
| Twitter Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | 2 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 69 | Sign up | Sign up | Sign up |
| Linkedin Employees | 901 | Sign up | Sign up | Sign up |
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
| Price | $131.87 |
| Target Price | Sign up |
| Volume | 15,440,000 |
| Market Cap | $14B |
| Year Range | $71.19 - $131.92 |
| Dividend Yield | 0% |
| Analyst Rating | 36% buy |
| Industry | Biotechnology |
In the news
 |
Sterling Capital Management LLC Has $139,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)April 22 - ETF Daily News |
 |
Intra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.comApril 21 - ETF Daily News |
|
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Position Decreased by Russell Investments Group Ltd.April 18 - ETF Daily News |
|
Envestnet Asset Management Inc. Sells 2,317 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)April 18 - ETF Daily News |
|
Legal & General Group Plc Sells 8,681 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)April 17 - ETF Daily News |
|
StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)April 14 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 175M | 132M | 43M | -26M | -39M | -0.250 |
| Q2 '24 | 161M | 122M | 40M | -16M | -28M | -0.160 |
| Q1 '24 | 145M | 113M | 32M | -15M | -21M | -0.160 |
| Q4 '23 | 132M | 105M | 132M | -29M | -34M | -0.300 |
| Q3 '23 | 126M | 105M | 21M | -24M | -30M | -0.250 |
Insider Transactions View All
| Mates Sharon filed to sell 1,070,329 shares at $84.7. December 6 '24 |
| Mates Sharon filed to sell 1,071,863 shares at $84.1. December 6 '24 |
| Mates Sharon filed to sell 1,070,329 shares at $86. December 6 '24 |
| Mates Sharon filed to sell 1,093,662 shares at $85.6. December 6 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Josh Gottheimer |
Apr 11, 25 | Sell | $1K - $15K |
| Gil Cisneros |
Apr 8, 25 | Sell | $1K - $15K |
| Josh Gottheimer |
Feb 11, 25 | Sell | $1K - $15K |
Read more about Intra-Cellular Therapies (ITCI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Intra-Cellular Therapies?
The Market Cap of Intra-Cellular Therapies is $14B.
What is the current stock price of Intra-Cellular Therapies?
Currently, the price of one share of Intra-Cellular Therapies stock is $131.87.
How can I analyze the ITCI stock price chart for investment decisions?
The ITCI stock price chart above provides a comprehensive visual representation of Intra-Cellular Therapies' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Intra-Cellular Therapies shares. Our platform offers an up-to-date ITCI stock price chart, along with technical data analysis and alternative data insights.
Does ITCI offer dividends to its shareholders?
As of our latest update, Intra-Cellular Therapies (ITCI) does not offer dividends to its shareholders. Investors interested in Intra-Cellular Therapies should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Intra-Cellular Therapies?
Some of the similar stocks of Intra-Cellular Therapies are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.